"What excites me the most is ensuring everything, no matter how many things we have in the air at once, is executed flawlessly" Imagine the multitasking capabilities of an air traffic controller, only for ALS drug development. Our COO, Hagit Binder, shares how she masters this complex challenge ?? #OurStory #NeuroSenseTherapeutics #NRSN
NeuroSense Therapeutics
生物技术研究
Cambridge，Massachusetts 9,226 位关注者
Creatively and diligently moving fast towards an effective treatment for people with ALS.
关于我们
Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally. $NRSN
- 网站
-
https://www.neurosense-tx.com/
NeuroSense Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2017
- 领域
- Drug Development、ALS、MND、Lou Gehrig's Disease、CNS、Biopharmaceuticals、Neurodegenerative Diseases、Parkinson's Disease、Alzheimer's disease和Novel treatment
地点
NeuroSense Therapeutics员工
-
Ron Meitar
-
Roy Golan
Financial Advisor, Investor and a Board Member
-
Alon Ben-Noon
CEO & Co-Founder @ NeuroSense Therapeutics | Advancing CNS Drug Development
-
Tal Peleg-Shulman, PhD, LLB Adv.
Senior Executive | Early-Stage Startup Advisor & Mentor | Angel Investor | Social Impact Advocate | Healthcare Regulatory Strategy
动态
-
What’s the most exciting area of innovation in biotech today? ?? #Biotech #Genetherapy #mRNA #AI #PrecisionMedicine
此处无法显示此内容
在领英 APP 中访问此内容等
-
In appreciation and admiration of all caregivers everywhere, thank you for your unwavering dedication. You are the heart of the community, and we stand with you. #FamilyCaregiversMonth #ALS #HopeForACure #CaregiversMatter
-
-
“It is especially important to create strong relationships with all of the people involved in the study to make sure that there is effective collaboration” Vered Sasson ????, our talented lead CRA, shares her insights on fostering teamwork?and meticulousness in clinical?studies ?? #OurStory #NeuroSenseTherapeutics #NRSN
NeuroSense featuring the Lead CRA - Neurosense
https://www.neurosense-tx.com
-
Great meetings in NYC NeuroSense Therapeutics Michael Rabinowitz #als
-
-
Join us on Thursday at the ALS ONE meeting, where Prof. Merit Cudkowicz & Dr. Shiran Zimri will share our latest results #ALSTherapy #ALSResearch #NRSN #PARADIGM
-
-
“The feeling of successfully navigating the regulatory landscape and achieving drug approval is indescribable” Don't miss Diana Shtossel's insights on the complex world of neurodegenerative disease regulations.??? #OurStory #NeuroSenseTherapeutics #NRSN
NeuroSense featuring the VP Regulatory Affairs - Neurosense
https://www.neurosense-tx.com
-
NeuroSense $NRSN Moves Toward Early Commercialization Of #ALS Treatment In Canada ???? , Eyeing $100M+ Market ?? Learn more about NeuroSense Therapeutics' #PrimeC drug candidate here ?? https://lnkd.in/efJ-YiTN #biotech #ad
-
“The most rewarding aspect of leading NeuroSense is hearing how we have improved people’s lives”?Alon Ben-Noon ???? Check out our CEO's blog ?? #OurStory #NeuroSenseTherapeutics #NRSN
NeuroSense featuring the CEO - Neurosense
https://www.neurosense-tx.com
-
“Do things right the first time” Meet Dorit Jacob, our Regulatory Affairs Director, and read all about what goes on behind the scenes of advancing therapies towards approval?? #OurStory #NeuroSenseTherapeutics #NRSN
NeuroSense featuring the Regulatory Affairs Director - Neurosense
https://www.neurosense-tx.com